良性前列腺增生相关的前列腺特异性膜抗原-正电子发射断层扫描在前列腺癌诊断中的假阳性:免活检根治性前列腺切除术的致命弱点?
该回顾性研究纳入因临床怀疑前列腺癌而接受PSMA-PET且确诊为良性前列腺增生或前列腺癌的患者,发现良性前列腺增生相关的PSMA-PET假阳性率为30%。最大标准化摄取值可有效排除良性前列腺增生和Grade Group 1患者,曲线下面积为0.86;严格PET评分与PI-RADS标准(均≥4)诊断临床显著前列腺癌的敏感性和特异性分别为49%和100%。
要点
- 良性前列腺增生相关的PSMA-PET假阳性率为30%。
- 最大标准化摄取值排除良性前列腺增生和Grade Group 1的AUC为0.86。
- 严格PET评分与PI-RADS均≥4诊断临床显著前列腺癌敏感性49%、特异性100%。
核心结论
- 研究发现良性前列腺增生相关的PSMA-PET假阳性率,并为免活检根治性前列腺切除术提供初步参考。
研究设计与样本
- 回顾性研究,纳入因临床怀疑前列腺癌而接受PSMA-PET并确诊为良性前列腺增生或前列腺癌的患者。
主要发现
- 良性前列腺增生相关的PSMA-PET检测前列腺癌的假阳性率为30%。
- 最大标准化摄取值可有效排除良性前列腺增生和Grade Group 1患者,曲线下面积为0.86。
- 以100%特异性为条件的最佳最大标准化摄取值截断值为15,敏感性为41%。
- 严格PET评分和PI-RADS标准(两者均≥4)诊断临床显著前列腺癌的敏感性和特异性分别为49%和100%。
关键数值与推荐
- 最大标准化摄取值以100%特异性为条件的最佳截断值为15,敏感性为41%。
- 严格PET评分和PI-RADS标准均≥4诊断临床显著前列腺癌的敏感性为49%,特异性为100%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radical prostatectomy is one of the primary treatments for localized clinically significant prostate cancer. Generally, its application is based on prior biopsy. PSMA (prostate-specific membrane antigen)-PET (positron emission tomography) is considered promising in biopsy-free radical prostatectomy. The expression of PSMA in benign prostatic hyperplasia tissue and corresponding positive reaction are crucial concerns for a no-biopsy strategy. Currently, no study has explored the benign prostatic hyperplasia-related false-positive of PSMA-PET in the detection of prostate cancer. Furthermore, the influence of maximum standardized uptake value and Prostate Imaging Reporting & Data System on biopsy-free radical prostatectomy is also poorly characterized. MATERIALS AND METHODS: A retrospective study was conducted on patients who received PSMA-PET because of clinical suspicion of prostate cancer and were confirmed to have benign prostatic hyperplasia or prostate cancer. The receiver operating characteristic curve was generated for maximum standardized uptake value. Results of interest were the false-positive rate of PSMA-PET and the efficacy of maximum standardized uptake value or multiparametric MRI in excluding false-positives. RESULTS: The benign prostatic hyperplasia-related false-positive rate of PSMA-PET in detecting prostate cancer was 30%. Maximum standardized uptake value could effectively exclude benign prostatic hyperplasia and Grade Group 1 patients with an area under the curve of 0.86; the optimal maximum standardized uptake value cutoff value with 100% specificity was 15, with a sensitivity of 41%. Notably, the sensitivity and specificity of stringent PET score and Prostate Imaging Reporting & Data System criteria (both ≥4) in diagnosing clinically significant prostate cancer were 49% and 100%, respectively. CONCLUSIONS: Our findings revealed benign prostatic hyperplasia-related false-positive rate of PSMA-PET and provided a preliminary reference in biopsy-free radical prostatectomy.
引用
- Tang W, Tang Y, Qi L, et al. Benign Prostatic Hyperplasia-Related False-Positive of Prostate-Specific Membrane Antigen-Positron Emission Tomography in the Diagnosis of Prostate Cancer: The Achilles' Heel of Biopsy-Free Radical Prostatectomy? J Urol. 2023. PMID: 37647549. doi:10.1097/JU.0000000000003680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。